epirubicin

P2, N=144, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2026

According to the differences in NAC regimens, they were categorized into TCb group (n=50), docetaxel + doxorubicin + cyclophosphamide (TAC group, n=60), and epirubicin combined with cyclophosphamide followed by docetaxel (EC-T group, n=40). TNBC patients with high levels of NPAR, severe neutropenia, high Ki-67 expression, and lymph node stage I are more likely to achieve pCR. In addition, NPAR, Ki-67 expression and severe neutropenia were all good predictors of pCR, the better performance in predicting pCR after combining multiple metrics.

This case demonstrates the diagnostic complexities of PTL with gonadal vein tumor thrombus, underscoring the importance of considering lymphoma in elderly patients with testicular masses and venous involvement. A multi-disciplinary team including urologists, hematologists, and radiation oncologists is needed to ensure appropriate therapy.

Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment.

Epirubicin exerts anti-myeloma effects by downregulating CDC20 and inducing cell-cycle arrest in MM, highlighting CDC20 as a potential biomarker for identifying MM patients likely to benefit from epirubicin.

This study aimed to characterize time-dependent metabolic alterations and identify metabolites associated with treatment response in HER2-negative breast cancer patients undergoing neoadjuvant chemotherapy (NAC) with the TEC regimen (docetaxel, epirubicin, and cyclophosphamide)...Following six cycles, elevated epinephrine levels were positively associated with therapeutic efficacy, while increased cysteine levels were linked to unfavorable outcomes...Combined analysis of ursodeoxycholic acid and cysteine improved the predictive performance for treatment response. These findings reveal dynamic metabolic reprogramming during NAC and suggest that ursodeoxycholic acid and cysteine may serve as potential predictive biomarkers of therapeutic efficacy in HER2-negative breast cancer patients treated with the TEC regimen.

P4, N=2, Terminated, Ottawa Hospital Research Institute | Completed --> Terminated; The study did not meet the pilot feasibility endpoints and was formally closed to accrual prematurely on February 8, 2017.

P2, N=216, Not yet recruiting, Henan Cancer Hospital

Ten-year outcomes for TC and EC-T were similar and excellent; six cycles of TC is an effective option in HER2-negative eBC with pN0 or pN1 and intermediate-to-high-risk disease, according to gene expression analysis.

P2, N=302, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University

P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026

P3, N=550, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed